tiprankstipranks
Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial
PremiumThe FlyFate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial
4d ago
Fate Therapeutics presents 6-month data on first lupus patient
Premium
The Fly
Fate Therapeutics presents 6-month data on first lupus patient
4d ago
Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges
Premium
Company Announcements
Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges
9d ago
Fate Therapeutics reports Q2 EPS (33c), consensus (47c)
PremiumThe FlyFate Therapeutics reports Q2 EPS (33c), consensus (47c)
3M ago
Fate Therapeutics Appoints AI Expert to Enhance Board
Premium
Company Announcements
Fate Therapeutics Appoints AI Expert to Enhance Board
4M ago
Fate Therapeutics appoints Neely Mozaffarian to board of directors
Premium
The Fly
Fate Therapeutics appoints Neely Mozaffarian to board of directors
4M ago
Fate Therapeutics upgraded to Overweight from Neutral at Piper Sandler
PremiumThe FlyFate Therapeutics upgraded to Overweight from Neutral at Piper Sandler
5M ago
Fate Therapeutics Announces CFO Change and Shareholder Approvals
Premium
Company Announcements
Fate Therapeutics Announces CFO Change and Shareholder Approvals
6M ago
Fate Therapeutics CFO Resigns, CEO to Assume Role
Premium
Company Announcements
Fate Therapeutics CFO Resigns, CEO to Assume Role
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100